Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
J Acquir Immune Defic Syndr ; 61(3): 293-6, 2012 Nov 01.
Article in English | MEDLINE | ID: mdl-22828721

ABSTRACT

Mutations in the connection domain (CD) of reverse transcriptase have been implicated in reverse transcriptase inhibitor (RTI) resistance, but this is controversial and little is known in non-B subtype HIV-1. We determined CD mutations prevalence in a population infected predominantly with CRF02_AG and investigated associations with phenotypic RTI resistance. Detected CD mutations were G335D (82.3%), A371V (69.8%), E399D (9.4%), N348I (5.2%), V365I (4.2), Y318F (2.1%), G333E (2.1%), and A360V (2.1%). Mutations were largely polymorphic and did not confer RTI resistance. The observed trend toward reduced likelihood of etravirine or nevirapine resistance in the presence of G335D should be investigated further.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Reverse Transcriptase/genetics , Alkynes , Benzoxazines/pharmacology , Benzoxazines/therapeutic use , Binding Sites/drug effects , Binding Sites/genetics , Cyclopropanes , Deoxycytidine/analogs & derivatives , Deoxycytidine/pharmacology , Deoxycytidine/therapeutic use , Drug Resistance, Viral/genetics , Emtricitabine , HIV Infections/virology , HIV Reverse Transcriptase/antagonists & inhibitors , HIV-1/drug effects , HIV-1/enzymology , HIV-1/genetics , Humans , Mali , Mutation/genetics , Nevirapine/pharmacology , Nevirapine/therapeutic use , Phenotype , Treatment Failure
SELECTION OF CITATIONS
SEARCH DETAIL